Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte Responses

MY Mapara, 2004, Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance, J Clin Oncol, 22, 1136, 10.1200/JCO.2004.10.041

W Zou, 2005, Immunosuppressive networks in the tumour environment and their therapeutic relevance, Nat Rev Cancer, 5, 263, 10.1038/nrc1586

GA Rabinovich, 2007, Immunosuppressive strategies that are mediated by tumor cells, Annu Rev Immunol, 25, 267, 10.1146/annurev.immunol.25.022106.141609

P Zheng, 1998, Proto-oncogene PML controls genes devoted to MHC class I antigen presentation, Nature, 396, 373, 10.1038/24628

B Seliger, 1997, TAP off–tumors on, Immunol Today, 18, 292

C Uyttenhove, 1983, Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression, J Exp Med, 157, 1040, 10.1084/jem.157.3.1040

B Thurner, 1999, Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma, J Exp Med, 190, 1669, 10.1084/jem.190.11.1669

C Yee, 2002, Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells, Proc Natl Acad Sci U S A, 99, 16168, 10.1073/pnas.242600099

W Zou, 2008, Inhibitory B7-family molecules in the tumour microenvironment, Nat Rev Immunol, 8, 467, 10.1038/nri2326

J Weber, 1994, Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine, Cancer Res, 54, 1766

ZS Guo, 2006, De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model, Cancer Res, 66, 1105, 10.1158/0008-5472.CAN-05-3020

S Coral, 2002, 5-aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications, Clin Cancer Res, 8, 2690

L Calabro, 2005, Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications, J Cell Physiol, 202, 474, 10.1002/jcp.20133

JA Dubovsky, 2009, Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen, Clin Cancer Res, 15, 3406, 10.1158/1078-0432.CCR-08-2099

VV Konkankit, 2011, Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway, J Transl Med, 9, 192, 10.1186/1479-5876-9-192

S Coral, 1999, Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR), J Immunother, 22, 16, 10.1097/00002371-199901000-00003

A Serrano, 2001, Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment, Int J Cancer, 94, 243, 10.1002/ijc.1452

E Fonsatti, 2007, Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma: immunotherapeutic implications, Clin Cancer Res, 13, 3333, 10.1158/1078-0432.CCR-06-3091

WJ Magner, 2000, Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors, J Immunol, 165, 7017, 10.4049/jimmunol.165.12.7017

T Maeda, 2000, Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells, Blood, 96, 3847, 10.1182/blood.V96.12.3847

L Sigalotti, 2005, Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy, Semin Oncol, 32, 473, 10.1053/j.seminoncol.2005.07.005

PA Jones, 1980, Cellular differentiation, cytidine analogs and DNA methylation, Cell, 20, 85, 10.1016/0092-8674(80)90237-8

LR Silverman, 2002, Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol, 20, 2429

H Kantarjian, 2006, Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study, Cancer, 106, 1794, 10.1002/cncr.21792

JP Issa, 2004, Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies, Blood, 103, 1635, 10.1182/blood-2003-03-0687

W Blum, 2007, Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia, J Clin Oncol, 25, 3884, 10.1200/JCO.2006.09.4169

AF Cashen, 2010, Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia, J Clin Oncol, 28, 556, 10.1200/JCO.2009.23.9178

RA Juergens, 2011, Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer, Cancer Discov, 1, 598, 10.1158/2159-8290.CD-11-0214

Y Oki, 2008, Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia, Blood, 111, 2382, 10.1182/blood-2007-07-103960

HC Tsai, 2012, Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells, Cancer Cell, 21, 430, 10.1016/j.ccr.2011.12.029

LX Wang, 2012, IL-10 contributes to the suppressive function of tumour-associated myeloid cells and enhances myeloid cell accumulation in tumours, Scand J Immunol, 75, 273, 10.1111/j.1365-3083.2011.02662.x

H Reiter, 1979, Effect of thymidine on the survival of mice with EL4 tumors, Cancer Res, 39, 4856

JA Gollob, 2007, Decitabine up-regulates S100A2 expression and synergizes with IFN-gamma to kill uveal melanoma cells, Clin Cancer Res, 13, 5219, 10.1158/1078-0432.CCR-07-0816

D Odobasic, 2008, Distinct in vivo roles of CD80 and CD86 in the effector T-cell responses inducing antigen-induced arthritis, Immunology, 124, 503, 10.1111/j.1365-2567.2007.02802.x

L Chen, 1992, Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4, Cell, 71, 1093, 10.1016/S0092-8674(05)80059-5

SE Townsend, 1993, Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells, Science, 259, 368, 10.1126/science.7678351

L Ramarathinam, 1994, T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells, J Exp Med, 179, 1205, 10.1084/jem.179.4.1205

TC Wu, 1995, A reassessment of the role of B7–1 expression in tumor rejection, J Exp Med, 182, 1415, 10.1084/jem.182.5.1415

XF Bai, 2001, Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens, J Immunol, 167, 3936, 10.4049/jimmunol.167.7.3936

XF Bai, 2001, On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen, Cancer Res, 61, 6860